Abstract: The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.

Abstract: Aspects of the present disclosure describe techniques that involve an active stabilization of coherent controllers using nearby qubits. In an aspect, a quantum information processing (QIP) system for stabilizing phase damping in qubits is described that provides a first and a second qubit ion, measuring magnetic field fluctuations using the second qubit ion, and generates one or more magnetic fields based on the measured magnetic field fluctuations, the one or more magnetic fields being applied near the first qubit ion to cancel the magnetic field fluctuations to stabilize the phase damping of the first qubit ion. Another such QIP system performs provides a first and a second qubit ion, locks a local oscillator to a frequency reference associated with the second qubit ion, and tracks, using the local oscillator, a frequency of the first qubit ion based on the frequency reference. Methods associated with these QIP systems are also described.

Abstract: A method for detecting a two-qubit correlated dephasing error includes accessing a signal of a quantum system, where the quantum system includes a plurality of qubits. Every qubit has a nonzero rate of dephasing and some qubits have a nonzero rate of correlated dephasing. The signal further includes information about a matrix that includes diagonal elements and off-diagonal elements. The off-diagonal elements of the matrix are 2s-sparse. The method further includes performing randomized measurements of the off-diagonal elements of the matrix and recovering the matrix based on a direct measurement of the diagonal elements of the matrix.

Abstract: A quantum EIT-based optical switch includes a first waveguide, linear or nonlinear, a separate nonlinear waveguide evanescently coupled to the first waveguide, and a pump coupled to the nonlinear waveguide. A quantum STIRAP-based optical transduction device, which includes an auxiliary, intermediate spectral state for the quantum signal that aids efficient transduction of the quantum signal from the input spectral state to the output spectral state in a single device.

Abstract: Compositions and methods for modifying genomic DNA sequences of a plant cell are provided. The methods produce double stranded breaks at target sites in a genomic DNA sequence, resulting in mutation, insertion, and/or deletion of DNA sequences at the target site(s) in a genome. The compositions comprise DNA constructs comprising nucleotide sequences that encode a Cas12b protein. The DNA constructs can be used to direct the modification of genomic DNA at a target site. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided.

Abstract: This invention relates to methods and systems of procuring services in the cloud and specifically procurement where the requirements are defined by the consumer in a machine understandable knowledge representation language such as RDF and OWL using semantic web technology to establish a cloud agent for discovery of a service provider and effectuate the automatic generation of a contract, or service-level agreement, that can be monitored due to the coupling between the machine understandable knowledge representation language and the contract.

Abstract: Systems and methods of quantum sensing include depositing a sample volume onto an ensemble of quantum defects, hyperpolarizing spins in the sample volume, performing a sensing sequence, and reading out information regarding electronic spin states of the quantum defects in the ensemble of quantum defects, which sense the hyperpolarized spins in the sample volume.

Abstract: The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.

Abstract: A thermo-responsive ultrasound coupling gel that contains a thermo-responsive polymer such as poly (n-isopropyl acrylamide), the gel having a phase shift at a temperature in the range of 32 to 35° C. such that the gel has a loss factor G?/G? of >1 at <32° C. and a loss factor G?/G? of <1 at >35° C. The gel can also contain at least one of a solvent and gelling agent. Methods and uses for the thermo-responsive ultrasound coupling gel in an ultrasound and/or ultrasound guided procedure.

Abstract: Disclosed is a system and method for the placement of elongate medical members within a patient's body using coaptive ultrasound that combines magnetic guidance with ultrasound visualization of the medical member in the patient's body. A coaptive ultrasound probe adaptor magnetically attracts an elongate medical member within the patient with sufficient force so as to allow the operator to manually guide the member to its intended location. The adaptor mates with an ultrasound probe to provide the medical operator ultrasound feedback of the position of the member, thus allowing internal placement without the need for more specialized medical equipment.

Abstract: Provided herein is a method for treating a cancer in a subject by quantitating the concentration of a soluble form of Semaphorin 4D (sSema4D) in a blood sample obtained from the subject and administering an immunotherapy when the blood concentration of sSema4D is below a threshold value of 155 ng/ml. Also provided is a method for determining the continued susceptibility of a tumor tissue to immunotherapy in a subject by identifying the inflammatory subtype of the tumor tissue from a blood sample from the subject and administering immunotherapy over at least one interval as long as the tumor tissue exhibits an inflamed subtype.

Abstract: A tissue anchor deployment device includes a needle having a slotted portion including a longitudinal slot that runs from a distal end of the needle and a suture having a first coil portion including a plurality of turns that wrap around a first portion of the slotted portion of the needle, a second coil portion including a plurality of turns that wrap around a second portion slotted portion of the needle that is proximal to the first portion of the slotted portion of the needle, and an internal coupling portion that runs within the first coil portion and the second coil portion and couples a distal end of the first coil portion to a proximal end of the second coil portion.

Abstract: Systems, methods, network devices, and machine-readable media disclosed herein include encoding data for storage or transmission by encoding the data according to a tamper-resistant data encoding scheme that renders the data secure against unbounded polynomial size attacks. The present disclosure further includes subsequently determining whether the data has been tampered with, and notifying a processor when the data has been modified or compromised.

Abstract: The present invention relates to a doped cubic bismuth oxide that is phase stable in a temperature range of from about 550° C. to about 700° C. The doped cubic bismuth oxide comprises a mixture of a first dopant and a second dopant.

Abstract: A bioprocessing system for protein manufacturing from human blood is provided that is compact, integrated and suited for on-demand production and delivery of therapeutic proteins to patients. The parent's own blood can be used as the source of cell extracts for the production of the therapeutic proteins.

Abstract: The present invention relates to rhomboidal phase bismuth oxide that maintains electric conductivity of at least about 1×10?2 S/cm at temperature of about 500° C. for at least about 100 hours. In particular, the bismuth oxides of the invention have stable conductivity at a temperature range from about 500° C. to about 550° C.

Abstract: A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery.

Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.

Abstract: A system for noise-resistant quantum communication using hyperentanglement includes a quantum system that includes a plurality of qubits, a processor, and a memory. The memory includes instructions stored thereon, which, when executed by the processor, cause the quantum system to access a signal of a quantum system that includes a plurality of qubits and obtain hyperentanglement of the plurality of qubits via an entanglement source. The hyperentanglement of the plurality of qubits is in at least two dimensions, including a first dimension and a second dimension. The instructions, when executed, further cause the quantum system to transmit the hyperentangled plurality of qubits via a communication channel; perform a communication of the signal with the first dimension of the at least two dimensions; and filter results of the communicated signal based on the second dimension of the at least two dimensions.

Abstract: Aspects of the present disclosure describe techniques for controlling coherent crosstalk errors that occur in multi-channel acousto-optic modulators (AOMs) by applying cancellation tones to reduce or eliminate the crosstalk errors. For example, a method and systems are described that include applying a first radio frequency (RF) tone to generate a first acoustic wave in a first channel of the multi-channel AOM, wherein a portion of the first acoustic wave interacts with a second channel to cause a crosstalk effect, and applying a second RF tone to generate a second acoustic wave in the second channel, wherein the second acoustic wave reduces or eliminates the crosstalk effect caused by the portion of the first acoustic wave.